Burden of recurrent CV events

In the US, there are an estimated 805,000 AMIs per year; 25% of these are recurrent AMIs.1

AMI carries a high mortality rate, with most deaths occurring prior to arriving at the hospital. Of those who make it, at least 5-10% will die within the first 12 months, and close to 50% will need to be rehospitalized within the first year.2

The estimated incidence of new AMI vs. recurrent MI1

Adapted from Virani et al. 20201


Recurrent CV events in the first year

~50% of recurrent CV events in the first year occurred in the 90-day high-risk period following an AMI3,4

Recurrent CV events post AMI are more serious and are associated with worse outcomes than the first. In the 90-day high-risk period after an AMI, patients have a high risk of all-cause mortality, CV death, and recurrent CV events.3,5,6

In a pooled analysis of 7 landmarks, clinical trials representing a total of 82,727 high‐risk patients with the recent acute coronary syndrome, half of the recurrent events occurred in the first 90 days of the 1-year follow-up period.4


The risk of recurrent CV events in the 1-year follow-up period4

Adapted from Chi et al. 20224


In a large-scale Swedish registry study, the cumulative rate of the primary composite endpoint (AMI, stroke or CV death) was approximately 10% and 18.3% during the first 90 days and 12 months, respectively, following the index AMI.3


Estimated risk of recurrent CV events in the first 365 days after the index AMI – stratified by age and risk3

Adapted from Jernberg et al. 20153


Cost of recurrent CV events


Recurrent CV events are associated with significant healthcare resource costs, with rehospitalization accounting for around 45% of total medical costs in the first year after an AMI.7–9

The average costs for a recurrent CV event in the US ($17,705) are just as high as for the index event ($16,981).10

Experts agree that the rate of recurrent CV deaths post AMI remains unacceptably high.1,11,12

Continue to

Current standard of care post AMI

Current standard of care and newer therapies have lowered the long-term risk of recurrent CV events; however, data show that patients are still at risk during the 90-day high-risk period after an AMI12–19

Expert views

These resources are for healthcare professionals to learn more about the role of cholesterol efflux and support their patients after an AMI

The cholesterol story

Learn about the role of cholesterol efflux in removing excess cholesterol from lipid-laden macrophages in arterial plaque20,21

Get the latest news

Sign up to receive news alerts and information about educational resources to help your patients through the 90-day high-risk period post AMI

By submitting this form, you are consenting to disclose any information provided, including your name, email address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may be contacted by mail, email, telephone, and/or SMS/text message in relation to our business, products, services, and educational programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt-out from receiving communications from CSL Behring Entities at any time. CSL Behring and CSL Behring Entities will not sell your personal information. CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy


AMI, acute myocardial infarction; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction


1. Virani SS et al. Circulation 2020; 141:e139–e596.

2. Mechanic OJ et al. Acute myocardial infarction. In: StatPearls [Internet], 2022. Treasure Island (FL): StatPearls Publishing.

3. Jernberg T et al. Eur Heart J 2015; 36:1163–1170.

4. Chi G et al. Clin Cardiol 2022; 45:299–307.

5. Norgaard ML et al. Diabetologia 2010; 53:1612–1619.

6. Nakatani D et al. Circ J 2013; 77:439–446.

7. Bakhai A et al. J Interv Cardiol 2012; 25:19–27.

8. Punekar RS et al. Clin Cardiol 2015; 38:483–491.

9. Zhao Z, Winget M. BMC Health Serv Res 2011; 11:35.

10. Chapman RH et al. BMC Cardiovasc Disord 2011; 11:11.

11. Song J et al. Heart 2020; 107:313–318.

12. Nair R et al. J Am Heart Assoc 2021; 10:e019270.

13. Schwartz GG et al. N Engl J Med 2018; 379:2097–2107.

14. Cannon CP et al. N Engl J Med 2015; 372:2387–2397.

15. Schwartz GG et al. JAMA 2001; 285:1711–1718.

16. Bhatt DL et al. N Engl J Med 2019; 380:11–22.

17. Bhatt DL et al. J Am Coll Cardiol 2019; 73:2791–2802.

18. Mehta SR et al. N Engl J Med 2019; 381:1411–1421.

19. Wallentin L et al. N Engl J Med 2009; 361:1045–1057.

20. Silvain J et al. Curr Opin Cardiol 2019; 34:714–720.

21. Estrada-Luna D et al. Molecules 2018; 23:2730.


USA-GEN-0051 | October 2022